Date receipt dossier
EudraCT number
2014-003060-20
Company / Sponsor
Novartis Pharma Services AG
Phase
II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Leukemia
Therapeutic approach
Immunotherapy
Genetic modification
Chimeric antigen receptor against CD19
Method of transfer of nucleic acid of interest
Lentiviral vector
Administered biological material
T-cells transduced with lentiviral vector expressing anti-CD19 CAR
Route of administration
Intravenous
Locations in Belgium
UZ Gent
Type of procedure
Contained use only
Current status
Authorized